Journal article

Erenumab for chronic cluster headache: A case report

  • 2020-9-22
Published in:
  • Cephalalgia Reports. - SAGE Publications. - 2020, vol. 3, p. 251581632094771
English The preventive treatment for cluster headache is often limited by a lack of efficacy or side effects. Calcitonin gene-related peptide (CGRP) has been implicated in the pathophysiology of cluster headache. Galcanezumab, a monoclonal antibody against calcitonin gene-related peptide (CGRP), significantly reduced the frequency of episodic cluster headache attacks. We report the case of a 38-year-old woman with chronic refractory cluster headache and comorbid migraine who received erenumab in 4 repeated doses of 70 mg subcutaneously over 25 weeks. Attack frequency decreased from three attacks per day to several attacks per week. Erenumab seemed to be highly effective in the prevention of cluster headache attacks in this patient. We suggest that randomized control trials should be performed.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/121519
Statistics

Document views: 23 File downloads:
  • fulltext.pdf: 0